Company: SRPT
Filing Date: 2025-06-06
Form Type: 8-K
Source: 0000950170-25-083131
Chunk: 2

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-06-06
Form: 8-K
Item: Item 5.07
Chunk 2
---
      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────
  71,084,947      3,248,699       50,354            10,202,114  

Proposal 4: Amendment to the Company’s Amended and Restated 2013 Employee Stock Purchase Plan

The stockholders approved the 2016 ESPP Amendment. The results of the vote were as follows:

         For      Against      Abstain      Broker Non-Votes  
 ──────────────────────────────────────────────────────────────
  73,725,724      629,170       29,106            10,202,114  

Proposal 5: Ratification of KPMG as the Company’s Independent Registered Public Accounting Firm

The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2025. The results of the vote were as follows:

         For        Against      Abstain  
 ──────────────────────────────────────────
  80,588,115      3,875,497      122,502  

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit      Description                                                                                                                              
   Number                                                                                                                                               
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
     10.1      Amendment No. 4 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan                                                             
     10.2      Amendment No. 3 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan                                 
      104      The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101